Screener
Crinetics Pharmaceuticals CRNX Business Segments — Income Tax
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2025
- Accession
- 0001658247-26-000012
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| External selling, general and administrative expenses | (90,013) | (38,733) | (20,362) |
| Selling, general and administrative personnel expenses | (60,638) | (32,285) | (19,428) |
| Selling, general and administrative stock-based compensation | (40,680) | (28,719) | (18,304) |
| Total selling, general and administrative expenses | (191,331) | (99,737) | (58,094) |
| Total other income, net | 51,632 | 40,916 | 13,277 |
| Income tax expense | (180) | — | — |
| Loss on equity method investment | — | (470) | (5,198) |
| Segment and consolidated net loss | $(465,317) | $(298,408) | $(214,529) |
Item 16. Form 10-K Summary
FAQ
- What is Crinetics Pharmaceuticals's business segments — income tax?
- Crinetics Pharmaceuticals (CRNX) reported business segments — income tax of $45K in Q4 2025.
- What does business segments — income tax mean?
- Reflects the total tax liability recognized by the company based on its taxable income in various jurisdictions. Even for companies reporting net losses, this may include deferred tax adjustments or taxes paid in specific profitable regions. It is a standard measure of the company's tax burden and regulatory compliance costs.
Ask your AI about Crinetics Pharmaceuticals's business segments — income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude